By A O News Service
NAHARLAGUN, May 22: The CoWIN, developed by the central government for vaccination drive, is a dynamic portal with multiple facilities, including registration, availability of vaccine, intimation to beneficiaries, vaccine status, vaccine centre and vaccination certificate, said state immunization officer Dr Dimong Padung.
Responding to various questions that many intending beneficiaries were showing with common query as to why no name in portal even after registration, Dr Padung said that the vaccination drive with indigenously built Covishield and Covaxin vaccines was launched in India on January 16 with a gap of four-six weeks between two doses.
While the gap between inoculations of Serum Institute of India (SII) developed Covishield has been extended several times, but it remained same for Covaxin, developed by Bharat Biotech.
The Centre again revised the gap between the two doses of Covishield – a COVID-19 vaccine manufactured by the last week.
Later, the Centre revised it to four-eight weeks. Last week, it said that the doses of the vaccine are to be administered 12-16 weeks apart, following a recommendation by a government
While the gap between inoculations of Covishield has been extended several times, it has remained unchanged for Covaxin – developed by Bharat Biotech.
The reason behind the extension of the gap for Covishield, but not for Covaxin, has been determined by the effectiveness of the first dose of the vaccine, he said quoting report of Indian Council of Medical Research (ICMR).
Thus, once first dose is administered, it would be uploaded to the CoWIN followed by automatic issue of certificate. But, as Covishield is administered in the state, the name would appear only after the end o prescribed gap. Neither the name would appear before that nor inoculation would generate certificate, he added.
Moreover, he also advised those with severe allergic reactions to foods, oral medications may get vaccinated, but those with a severe allergic reaction (anaphylaxis) to any vaccine or injectable (intramuscular or intravenous) medication should consult with their health provider to assess risk before vaccination.
However, pregnant or lactating women, people with high fever or bleeding disorders, those having history of allergies, serious health issues should not take the jab, he said, adding the second dose should be of the same vaccine only.
